CytoMed Therapeutics Overview
Latest P/E ratio for CytoMed Therapeutics: -3.0 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-3.00
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
CytoMed Therapeutics (GDTC) currently reports a P/E ratio of -3.0. That is below the sector sector average of 40.88. Use the charts on this page to explore CytoMed Therapeutics's P/E ratio history and peer comparisons.
CytoMed Therapeutics's P/E ratio of -3.0 is lower than the its sector sector average of 40.88. That is roughly 107.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates CytoMed Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -3.0, GDTC can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -3.0, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 40.88. From there, open related valuation or income-statement pages for CytoMed Therapeutics, and consider following GDTC for alerts when major investors trade the stock.
